Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ixempra

- PMLiVE

GSK loses patent on Tykerb in India

Cuts period of exclusivity by two years

Roche - Basel

Roche cuts cost of drug to prevent blindness in HIV patients

Will improve access to Valcyte in developing nations

- PMLiVE

Merck profit slides as generics continue to bite

Singulair, Maxalt, Cozaar and Clarinex sales all affected

- PMLiVE

Pfizer separates branded and generic divisions

Follows spin out of animal health and nutrition

Bristol-Myers Squibb (BMS) building

BMS signs 10-year biologic manufacturing deal with Samsung

Agreement covers one of the pharma company's antibody cancer drugs

- PMLiVE

AZ and BMS try again with Forxiga in the US

Pharma companies re-submit diabetes drug to the FDA for approval

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

Roche - Basel

Roche antibody tops Rituxan in blood cancer CLL

Obinutuzumab on course for leukaemia approval by year-end

- PMLiVE

UCB files Vimpat patent claims against 15 companies

Aurobindo, Glenmark, Mylan, Ranbaxy and Sandoz all face legal challenge over generic versions of UCB's epilepsy drug

- PMLiVE

NICE demands more data from Roche for MabThera in rare autoimmune disease

Unable to recommend expanding drug’s indication to include vasculitis

- PMLiVE

Analysts question value of rumoured $20bn Roche bid for Alexion

Shares in orphan drug specialist slide back after earlier surge

- PMLiVE

Intellectual property threats in the BRIC markets

Compulsory licensing and other legal concerns for pharma in emerging markets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links